2008
DOI: 10.1016/j.antiviral.2008.01.156
|View full text |Cite
|
Sign up to set email alerts
|

Anti-HSV activity of digitoxin and its possible mechanisms

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
64
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 78 publications
(66 citation statements)
references
References 48 publications
2
64
0
Order By: Relevance
“…Digitoxin impaired the HSV viral life cycle at two different steps: viral DNA synthesis and viral release form the host cells. The authors also showed that others cardiac glycosides such as digoxin, ouabain, and G-strophanthin have comparable anti-HSV activity [19]. Finally, adenoviruses, which are common human pathogens, are also susceptible to cardiac glycosides such as digitoxin and digoxin, which are able to impair adenovirus genome replication by altering the host pre-RNA splicing machinery [39].…”
Section: Dna Viruses Affected By Nak-atpase Modulationmentioning
confidence: 99%
“…Digitoxin impaired the HSV viral life cycle at two different steps: viral DNA synthesis and viral release form the host cells. The authors also showed that others cardiac glycosides such as digoxin, ouabain, and G-strophanthin have comparable anti-HSV activity [19]. Finally, adenoviruses, which are common human pathogens, are also susceptible to cardiac glycosides such as digitoxin and digoxin, which are able to impair adenovirus genome replication by altering the host pre-RNA splicing machinery [39].…”
Section: Dna Viruses Affected By Nak-atpase Modulationmentioning
confidence: 99%
“…The cytotoxicity assay of the samples was determined according to the method of Su et al (2008) by MTT assay. In brief, cells were plated at 2 × 10 4 cells per well in 96 well microtiter plates (Costar 3599, Corning, NY, USA) with 100 μL RPMI-1640 growth medium and incubated for 24 h at 37°C, with 5% CO 2 in a humidified atmosphere (Incu-Safe, Sanyo, Japan), during which period a partial monolayer was formed.…”
Section: Cytotoxicity Assaymentioning
confidence: 99%
“…Acyclovir continues to be the reference drug for HSV diseases treatment even after three decades of its development [6]. However, in long-term treatment and especially in immunocompromised individuals, acyclovir can lead to the selection of resistant mutants [7]. These features highlight the need to develop new antiherpetic drugs.…”
Section: Introductionmentioning
confidence: 99%